Janus Henderson Group PLC lowered its stake in Exelixis, Inc. (NASDAQ:EXEL) by 3.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,127,292 shares of the biotechnology company’s stock after selling 37,506 shares during the period. Janus Henderson Group PLC owned approximately 0.38% of Exelixis worth $27,314,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC bought a new stake in shares of Exelixis in the third quarter worth about $120,000. Fisher Asset Management LLC bought a new stake in Exelixis during the 3rd quarter valued at approximately $213,000. Caxton Associates LP bought a new stake in Exelixis during the 2nd quarter valued at approximately $227,000. Raymond James Financial Services Advisors Inc. bought a new stake in Exelixis during the 3rd quarter valued at approximately $236,000. Finally, CIBC Asset Management Inc bought a new stake in Exelixis during the 3rd quarter valued at approximately $238,000. Hedge funds and other institutional investors own 81.15% of the company’s stock.
EXEL has been the topic of several research reports. Leerink Swann cut Exelixis from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $34.00 to $28.00 in a research report on Friday, September 22nd. Oppenheimer reiterated a “hold” rating on shares of Exelixis in a report on Monday, September 25th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Exelixis in a report on Monday, October 2nd. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a report on Tuesday, October 10th. Finally, Cann restated a “hold” rating on shares of Exelixis in a report on Monday, October 16th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $32.13.
Shares of Exelixis, Inc. (NASDAQ EXEL) traded up $0.30 during mid-day trading on Friday, hitting $30.38. 2,027,070 shares of the stock were exchanged, compared to its average volume of 2,550,000. Exelixis, Inc. has a 12-month low of $16.72 and a 12-month high of $32.50. The company has a market cap of $8,990.00, a P/E ratio of 62.00, a price-to-earnings-growth ratio of 0.90 and a beta of 1.88.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.18. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The firm had revenue of $152.50 million during the quarter, compared to the consensus estimate of $104.91 million. During the same quarter in the previous year, the firm posted ($0.04) EPS. The company’s revenue for the quarter was up 145.2% compared to the same quarter last year. equities research analysts expect that Exelixis, Inc. will post 0.49 earnings per share for the current year.
In related news, Director Alan M. Garber sold 15,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the transaction, the director now owns 64,829 shares of the company’s stock, valued at approximately $1,964,318.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2018/01/13/janus-henderson-group-plc-decreases-stake-in-exelixis-inc-exel-updated-updated.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.